Prolight‘s CEO to BioStock: “Roche’s acquisition highlights interest in Point-of-Care”
There is a high demand within healthcare for Point-of-Care systems. The field also attracts significant interest from leading diagnostics companies. This was recently demonstrated by Roche’s acquisition of LumiraDx’s Point-of-Care technology for USD 295 million. Ulf Bladin, CEO of Swedish POC company Prolight Diagnostics, comments on the acquisition and shares the company’s partnership ambitions in an interview with BioStock.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se